Michael Bennet

The story of this Denver replacement facility should have been about the government improving the delivery of care to our veterans, instead of how feckless and shortsighted it can be.

I do think we have complete agreement that we need to find the money and that we will finish the project.

There is no other option.

Globalization has put pressure on middle-class wages.

The central challenge we face has been the decoupling of wage growth and job growth from economic growth.

I also have meetings that I need to----

Lynn worked with this Committee and the full Senate to help secure a one-year extension of PILT payments during the conference committee for the 2014 Farm Bill.

The importance of clean water to the State of Colorado and to this country, you cannot put a value on it. It is absolutely priceless.

Thank you for allowing them to testify.

You have been one of the nation's leaders on this issue.

EPA's stated goal in this rulemaking is to restore the Clean Water Act to its historic reach.

Kent knows the importance of clean water to his farm, and that is why he is here today, to support the Clean Water Rule.

Antibiotic resistance remains a serious patient safety, public health, and national security concern.

We urge the committee to consider S. 185, the Promise for Antibiotics and Therapeutics for Health (PATH) Act, introduced by Senator Hatch and Senator Bennet.

This bill would allow FDA to approve these drugs on the basis of smaller amounts of data than it uses to approve other antibiotics.

Thank you very much for holding this hearing.

Thank you to the panel. I'm out of time.

Is there something you can do to help us with that? And that became breakthrough therapies.

Senators Hatch and Bennet have introduced the PATH Act, S. 185, which would direct FDA to create this pathway for antibiotics.

A number of key stakeholders, including public health groups, providers, industry, and venture capital, support this legislation.

Such resistant infections are on the rise and threaten to become a public health crisis.

Senator Hatch and I, as you know, have been working on legislation to require FDA to establish a new regulatory pathway.

I hope that's right, and I've heard the same thing from developers of these drugs.

It has succeeded beyond our wildest dreams, It's fair to say.

A number of years ago, the Colorado bioscience community came to me and said, 'We can't raise venture capital anymore in the United States. It's all going to Europe. It's all going to Asia.'